Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 20531297)

1.

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.

Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM.

Oncogene. 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7.

PMID:
20531297
2.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

3.

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM.

Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6.

4.

Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.

Spanheimer PM, Park JM, Askeland RW, Kulak MV, Woodfield GW, De Andrade JP, Cyr AR, Sugg SL, Thomas A, Weigel RJ.

Clin Cancer Res. 2014 Apr 15;20(8):2115-25. doi: 10.1158/1078-0432.CCR-13-2221. Epub 2014 Feb 13.

5.

HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, Goswami CP, Nakshatri H, Gupta R, Chang HY, Zhang Z, Cimino-Mathews A, Cope L, Umbricht C, Sukumar S.

Cancer Res. 2013 Sep 1;73(17):5449-58. doi: 10.1158/0008-5472.CAN-13-1178. Epub 2013 Jul 5.

6.

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H.

J Biol Chem. 2001 Mar 30;276(13):9817-24. Epub 2001 Jan 3.

8.

MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.

Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.

Oncogene. 2002 Jun 6;21(25):4000-8.

9.

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.

Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K.

Breast Cancer Res Treat. 2012 May;133(1):145-59. doi: 10.1007/s10549-011-1731-8. Epub 2011 Aug 24.

PMID:
21863258
10.

The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.

Shrivastav A, Bruce M, Jaksic D, Bader T, Seekallu S, Penner C, Nugent Z, Watson P, Murphy L.

Breast Cancer Res. 2014 May 22;16(3):R49. doi: 10.1186/bcr3660.

11.

Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.

Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.

J Natl Cancer Inst. 2006 May 17;98(10):671-80.

12.

VAV3 mediates resistance to breast cancer endocrine therapy.

Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.

Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664.

13.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

14.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.

Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.

Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.

PMID:
24463007
15.

O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.

Kanwal S, Fardini Y, Pagesy P, N'tumba-Byn T, Pierre-Eugène C, Masson E, Hampe C, Issad T.

PLoS One. 2013 Jul 11;8(7):e69150. doi: 10.1371/journal.pone.0069150. Print 2013.

16.

Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.

Glaros S, Atanaskova N, Zhao C, Skafar DF, Reddy KB.

Mol Endocrinol. 2006 May;20(5):996-1008. Epub 2006 Feb 2. Retraction in: Mol Endocrinol. 2008 Mar;22(3):772.

PMID:
16455819
17.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

18.

Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.

Jan R, Huang M, Lewis-Wambi J.

Breast Cancer Res. 2012 Nov 14;14(6):R146. doi: 10.1186/bcr3356.

19.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

20.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk